Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Item

http://www.wikidata.org/entity/Q34419382

Q34419382

about

Neurosteroids: endogenous role in the human brain and therapeutic potentials Neurosteroid replacement therapy for catamenial epilepsy Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease Diverse mechanisms of antiepileptic drugs in the development pipeline Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism Molecular mechanisms of antiseizure drug activity at GABAA receptors The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.Fragile X: leading the way for targeted treatments in autism.Manipulation of GABAergic steroids: Sex differences in the effects on alcohol drinking- and withdrawal-related behaviors.Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice.17beta-Nitro-5alpha-androstan-3alpha-ol and its 3beta-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities.Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol.Non-stereo-selective cytosolic human brain tissue 3-ketosteroid reductase is refractory to inhibition by AKR1C inhibitors.Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats.Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye.Synthetic neurosteroids on brain protection Effect of nucleus accumbens shell infusions of ganaxolone or gaboxadol on ethanol consumption in mice Targeted treatments for fragile X syndrome.Neuroprotective actions of neurosteroids Neurosteroids and GABA-A Receptor Function.Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy.Modulation of spinal GABAergic analgesia by inhibition of chloride extrusion capacity in mice.Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.A 17beta-derivative of allopregnanolone is a neurosteroid antagonist at a cerebellar subpopulation of GABA A receptors with nanomolar affinity.Neuroendocrine aspects of catamenial epilepsy Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice.Effect of ganaxolone and THIP on operant and limited-access ethanol self-administration.5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.Role of hormones and neurosteroids in epileptogenesis.The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability.Neurosteroid Agonist at GABAA receptor induces persistent neuroplasticity in VTA dopamine neurons.Clinical Potential of Neurosteroids for CNS Disorders.Neurosteroids are reduced in diabetic neuropathy and may be associated with the development of neuropathic pain.A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.Rescue of deficient amygdala tonic γ-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel γ-aminobutyric acid type A receptor-positive allosteric modulator.

P2860

Q24632113-D018C3DB-6EBF-4FD4-B83B-F8D0C139D7C7 Q24643667-51A5D270-BB39-40B2-BB92-D7A277ECA2E0 Q24644950-866C5EA7-2D29-4E37-97D0-7D124ADB3B3C Q24675330-EAFB56BC-DE01-4764-8A4E-B7310F07B3F6 Q26781265-DA476CD5-8D9A-415D-AC68-E1196F8EE732 Q28383216-969097F7-A0D2-4F73-BCB8-6FAF90FCEDD7 Q28681145-78D994B7-A5B4-4723-B5EA-7BB9066AD31C Q30385019-2B84D38A-F0D4-42A0-A323-C78F50CBE60F Q30435321-AF656629-DB7A-48E9-B171-BE3A1B5F6623 Q30477804-53F73064-9FD2-40A8-8EDA-4F57BAB51F89 Q33625400-AF64DF00-40C9-4030-89C6-A57876CCCC5C Q33693153-725FF8B0-F6B7-4FF6-912D-827F4BCB78EE Q33788111-7A938F80-2A43-4331-8EF4-2039286CB11C Q34006183-A5E6AE9E-E53F-4D90-B741-0DA03027B683 Q34127015-8D7D6DCD-62C6-4F49-8AEB-1DAB9E563E1A Q34198650-5BA0D859-243D-453C-A9F7-4AED0CAA94F0 Q34230612-D97898CB-BD1D-4034-95CC-AF12D50AFF4B Q34336607-9382079D-69D8-4228-8209-90B644AE5B36 Q34555539-5049644A-86C4-4C5C-B627-8054609AF56B Q35169910-C8EE0C6A-355B-4F05-9ED5-5315904E4A35 Q35546332-64467A07-21C6-4F36-B4D8-0005DC60CFFF Q35680726-A0C3B879-F4C0-4F3F-B84F-416209F7A294 Q35971511-A42AD6F0-CAA0-438F-A576-0E2F741BB338 Q35971833-69B890A2-DAFD-4D2C-9D59-94F115B4849F Q35971997-1DD4A3B7-4C81-4FA5-A110-B32A2EB8A067 Q36007778-AFD556D7-066D-417C-8FEC-1CC3EA9B50C2 Q36054271-435D5EA7-8502-4655-A96A-56BBCF8DFD75 Q36094304-6B9B3E06-1F06-486D-B67E-9D3423A0FEDD Q36173874-C4444E35-CE98-4BEB-A8C6-7F41C89EB72C Q36407349-F369F266-F533-450D-BF70-7F27840C979F Q36851428-F7D8AB69-7794-471A-9519-D14ECFBC3591 Q36984167-C730E31B-D852-4CF8-AFF5-0D84CAF88C37 Q37057683-CEDE984C-0716-4AE8-B6D4-78ADD83398C4 Q37227965-28032B9E-537E-427F-800E-9824E779CF37 Q37320505-329B32B5-1D43-4B34-B3AD-5CB4AE75F5EF Q37491621-D085318A-ACD0-452A-A646-298670B10A4F Q37643528-56AF8A5F-07DA-475F-A102-071100B16276 Q37693559-E9841566-0E17-43F8-8ACE-9236C3DA9592 Q41215871-6495C51C-1F06-4556-BBD0-57CE1A5AF99E Q41258644-48B82F3B-AB7E-463F-ADF2-0A01F5667EE3

P2860

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Item

http://www.wikidata.org/entity/Q34419382

description

1997 nî lūn-bûn

@nan

1997 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի մարտին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu